Trial Profile
Safety and efficacy of vandetanib as systemic treatment for patients with advanced and progressive medullary thyroid cancer
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 01 Sep 2015 New trial record